Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.50 |
| ▸ | PRCP | P42785 | 1/20 | 0.48 |
| ▸ | CTSL | P07711 | 2/20 | 0.48 |
| ▸ | CTSS | P25774 | 2/20 | 0.48 |
| ▸ | CTSK | P43235 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | PTAFR | P25105 | 1/20 | 0.46 |
| ▸ | CTSA | P10619 | 1/20 | 0.45 |
| ▸ | OXGR1 | Q96P68 | 1/20 | 0.45 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | CTSV | O60911 | 1/20 | 0.45 |
| ▸ | CTSB | P07858 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30795674 | 1.00 | ALDH1A1 (0.54) | ALDH1A1KMT2ASMN1; SMN2LMNARAB9A | |
| SCHEMBL5218642 | 1.00 | ALDH1A1 (0.54) | ALDH1A1KMT2ASMN1; SMN2LMNARAB9A | |
| SCHEMBL5888420 | 0.97 | ALDH1A1 (0.50) | ALDH1A1KMT2ASMN1; SMN2LMNARAB9A | |
| SCHEMBL5888153 | 0.94 | PRCP (0.54) | ALDH1A1KMT2ASMN1; SMN2LMNARAB9A | |
| SCHEMBL5888147 | 0.94 | PRCP (0.54) | ALDH1A1KMT2ASMN1; SMN2LMNARAB9A | |
| SCHEMBL5888533 | 0.82 | KMT2A (0.56) | ALDH1A1KMT2APRCP | |
| SCHEMBL5888528 | 0.82 | KMT2A (0.56) | ALDH1A1KMT2APRCP | |
| SCHEMBL5888341 | 0.81 | CTSL (0.49) | ALDH1A1KMT2AKCNA5CTSLCTSS | |
| SCHEMBL5215121 | 0.81 | CTSL (0.49) | ALDH1A1KMT2AKCNA5CTSLCTSS | |
| SCHEMBL5888499 | 0.79 | CTSL (0.49) | ALDH1A1KMT2AKCNA5PRCPCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7135472-B2 | 3-Heterocyclic benzylamide derivatives as potassium channel openers | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-11-14 | — | — | US | claimed |
| US-20040106621-A1 | 3-Heterocyclic benzylamide derivatives as potassium channel openers | BRISTOL-MYERS SQUIBB COMPANY | 2004-06-03 | — | — | US | claimed |
| WO-2024054807-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND TDP-43 MODULATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024050389-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-07 | — | — | WO | disclosed |
| US-7135472-B2 | 3-Heterocyclic benzylamide derivatives as potassium channel openers | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-11-14 | — | — | US | disclosed |
| US-20040106621-A1 | 3-Heterocyclic benzylamide derivatives as potassium channel openers | BRISTOL-MYERS SQUIBB COMPANY | 2004-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106621-A1 | 3-Heterocyclic benzylamide derivatives as potassium channel openers | KCNQ3, KCNQ5, KCNQ2 | ALDH1A1 1430/4885KMT2A 185/4885SMN1; SMN2 2762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.